Long-term outcomes of three-dimensional conformal radiation therapy combined with neoadjuvant hormonal therapy for Japanese patients with T1C-T2NOMO prostate cancer
Long-term outcomes of three-dimensional conformal radiation therapy combined with neoadjuvant hormonal therapy for Japanese patients with T1C-T2NOMO prostate cancer
复制标题
三维适形放射治疗联合新辅助激素治疗日本 T1C-T2NOMO 前列腺癌患者的长期结果
DOI：
10.1007/s10147-011-0326-z
复制
发表时间：
2011
期刊：
影响因子：
--
通讯作者：
Hiraoka M
中科院分区：
文献类型：
--
作者：
Mizowaki T;Takayama K;Norihisa Y;Ogura M;Kamba T;Inoue T;Shimizu Y;Kamoto T;Ogawa O;Hiraoka M
三维适形放射治疗（3D-CRT）联合新辅助激素治疗（NAHT）治疗日本T1 c-T2 N 0 M0前列腺癌患者的结局，在相对早期阶段开始补救激素治疗（SHT），方法59例日本T1 c-T2 N 0 M0前列腺癌患者接受根治性3D-对1999年1月至2003年1月期间的CRT进行了评价。中位年龄、初始前列腺特异性抗原（PSA）水平和NAHT持续时间分别为：72岁、9.4 ng/ml和6个月。70戈伊分35次给予，局限于前列腺±精囊。AHT没有管理后3D-CRT在任何patients.ResultsThe中位随访期为89个月。开始SHT时的中位PSA值为4.7 ng/ml（范围为0.1-21.6 ng/ml）。8年时的总体、疾病特异性、无PSA失败（基于Phoenix定义）和无SHT生存率分别为82.8%（95%置信区间[CI] 72.4-93.2）、100%、62.4%（47.1-77.8）和82.6%（71.3-94.0）。只有一个病人发展3级晚期toxic.ConclusionsThe PSA控制率在我们的一系列日本患者的T1 C-T2 N 0 M0期前列腺癌治疗与标准剂量的3D-CRT结合NAHT似乎至少与西方国家的报道，以及，患者有很好的结果。目前的结果可用作评价日本前列腺癌患者未来调强放疗剂量递增影响的基础数据。
BackgroundThe outcomes of three-dimensional conformal radiation therapy (3D-CRT) combined with neoadjuvant hormonal therapy (NAHT) in Japanese patients with T1c-T2N0M0 prostate cancer, with initiation of salvage hormonal therapy (SHT) at a relatively early phase, were analyzed.MethodsFifty-nine Japanese patients with T1c-T2N0M0 prostate cancer who received radical 3D-CRT between January 1999 and January 2003 were evaluated. The median age, initial prostate-specific antigen (PSA) level, and duration of NAHT were: 72 years, 9.4 ng/ml, and 6 months, respectively. Seventy Gy was given in 35 fractions confined to the prostate ± seminal vesicles. AHT was not administered after 3D-CRT in any patients.ResultsThe median follow-up period was 89 months. The median PSA value at the time of initiation of SHT was 4.7 ng/ml (range 0.1–21.6 ng/ml). The overall, disease-specific, PSA failure-free (based on the Phoenix definition), and SHT-free survival rates at 8 years were 82.8% (95% confidence interval [CI] 72.4–93.2), 100%, 62.4% (47.1–77.8), and 82.6% (71.3–94.0), respectively. Only one patient developed grade 3 late toxicity.ConclusionsThe PSA control rates in our series of Japanese patients with stage T1c-T2N0M0 prostate cancer treated with the standard dose of 3D-CRT combined with NAHT seemed at least comparable to those reported from Western countries; as well, the patients had excellent outcomes. The present outcomes can be used as basic data for evaluating the impact of dose escalation with intensity-modulated radiation therapy for Japanese patients with prostate cancer in the future.